Perspective Therapeutics, Inc. (CATX)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore 2 is below the required floor of 3 (and the 20-day average dollar volume of $4.67M is below the $5.00M liquidity floor), so no new long is admissible regardless of the chart; both entry types were evaluated — no pullback limit qualifies (countertrend: price 0.8535 below SMA50 2.02 with MACD −0.36, and below a declining SMA200 3.41 without a reclaim) and no breakout stop qualifies for production (a stop above 0.95 would give R/R ~1.86 but is barred by the same fundamental and liquidity floors, and one above the 1.02 swing high gives only R/R ~1.27).
Company overview
Perspective Therapeutics, Inc. develops, manufactures, and markets radiopharmaceutical products and medical devices aimed at treating cancer. Its flagship product, CS-1 Cesium-131 brachytherapy seeds, is used for various cancers including prostate, brain, and lung. The company operates globally and is headquartered in Richland, Washington.
Fundamental
weakPerspective Therapeutics has a strong cash position but lacks revenue and faces high dilution, making it speculative.
Pre-revenue radiopharma developer with a fortress-like net-cash position (~$198 million versus a $103 million market cap, runway into 2028) but no product revenue, a ~$123 million trailing net loss, an accelerating ~$108 million annual operating cash burn, 62% share dilution in twelve months and binary clinical risk. Fundamentals read as speculative, not investable on a short horizon.
Sentiment
fairSentiment is mixed with recent insider buying and clinical data offset by earnings misses and target cuts.
Dominant in-window catalyst is the announced Q3 2026 print (2026-11-09) — an EPS and revenue miss with a widening $32.4M net loss and three same-day sell-side price-target cuts (Wedbush $9→$7, Truist $11→$8, Piper $14→$8) — set against two material announced clinical readouts (VMT01 at SITC and VMT-α-NET at NANETS, both 2026-11-06) and a five-insider open-market buying cluster struck at $0.80–$1.00. Media polarity cooled from a positive baseline (+0.30, a single scored item on a degraded pull corroborated by 11 discovered on-topic items) to flat/mixed (+0.05 across 6 scored items), a mild deterioration to flat at moderate confidence; the Red-Flag Screen found no severe flag, but a moderate conflicting-catalyst flag fired and the moderate red-flag cap applies.
Technical
weakThe stock is in a strong downtrend with no bullish setup, despite a recent oversold bounce.
Bounce-only chart, no bullish confirmation stack. Price is below every trend reference (SMA20 1.13, SMA50 2.02, SMA200 3.41, EMA9 0.91, EMA21 1.21, daily VWAP 0.867) after a collapse from $3.48 on 2026-08-19 to $0.85 — including a −32.9% session on 2026-10-23 and a further −16.2% on 2026-11-03. Momentum is deeply oversold (RSI14 27.48, Williams %R −85.34) and the MACD histogram has turned faintly positive (+0.04 from −0.10 on 2026-11-03), which is a nascent countertrend bounce attempt, but MACD line/signal remain negative (−0.36/−0.40) and ADX14 50.74 read together with price below all MAs describes strong DOWN-trend strength, not accumulation. Volatility is extreme (ATR14 $0.16 = 18.75% of price; StdDev20 0.43) and turnover is fading (3-day average dollar volume ~$2.3M vs 20-day $4.67M). Nothing here qualifies as a 1–15 day bullish setup: the chart scores 2 (weak/oversold-bounce only).
You’re looking at 2026-11-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

